Trial intelligence / Profile preview

Linagliptin + Metformin Initial Combination in T2DM

NCT01708902Phase 3Completed

Sponsor
Boehringer Ingelheim
Start
Oct 2012
Primary completion
Apr 2014
Modality
Small Molecules
Countries
4
01

Overview

A Phase 3 trial of linagliptin in type 2 diabetes mellitus (T2DM), sponsored by Boehringer Ingelheim. Started Oct 2012; status: completed.

02

Drugs

linagliptin
03

Conditions

type 2 diabetes mellitus (T2DM)

Beyond the preview

Go deeper on NCT01708902.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01708902.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call